|
|||||
|
|
Lung adenocarcinoma with BRAF G469L mutation refractory to vemurafenib |
|
| Authors: | Oliver Gautschi Solange Peters Vincent Zoete Franziska Aebersold-Keller Klaus Strobel Bernhard Schwizer Astrid Hirschmann Olivier Michielin Joachim Diebold |
| Affiliation: | 1. Department of Medical Oncology, Luzerner Kantonsspital, Luzern, Switzerland;2. Department of Pathology, Luzerner Kantonsspital, Luzern, Switzerland;3. Department of Nuclear Medicine, Luzerner Kantonsspital, Luzern, Switzerland;4. Department of Pulmonology, Luzerner Kantonsspital, Luzern, Switzerland;5. The University Hospital Lausanne Cancer Center, Lausanne, Switzerland |
| Abstract: | BRAF V600E is an emerging drug target in lung cancer, but the clinical significance of non-V600 BRAF mutations in lung cancer and other malignancies is less clear. Here, we report the case of a patient with metastatic lung adenocarcinoma with BRAF G469L mutation refractory to vemurafenib. We calculated a structure model of this very rare type of mutated BRAF kinase to explain the molecular mechanism of drug resistance. This information may help to develop effective targeted therapies for cancers with non-V600 BRAF mutations. |
| Keywords: | Lung cancer BRAF Melanoma Vemurafenib Dabrafenib Biomarker Targeted therapy |
| 本文献已被 ScienceDirect 等数据库收录！ | |